Title: Production of nanoliposomal amphotericin B 0.4% topical gel as effective treatment for human acne vulgaris
Abstract:
Acne (also known as acne vulgaris) is a persistent chronic skin inflammatory condition of the pilosebaceous follicles that affects people all over the world. Acne is projected to affect 9.4% of the global population, ranking it eighth among skin diseases. Acne affects more than 85% of teenagers, and the disease can persist into adulthood which often occurs in females and accounts for two-thirds of dermatologist consultations for acne. The unique lesions can be characterized as either non-inflammatory (open/black and closed/white comedowns) or inflammatory (papules, pustules, nodules, and cysts), leading to scar development and pigmentation on the skin, necessitating prolonged and persistent therapy. Typically, lesions are observed on the face, neck, upper back, and chest. Acne can’t be stopped from occurring or cured, but it can be treated quite successfully. Moreover, acne is also connected with significant financial expenses. It is noteworthy that the number of research papers and scientific findings relevant to acne treatment regimens continues to increase, given the enormous interest in various research breakthroughs in this area. Much study has been conducted on acne, both in terms of the disease process and the numerous therapy approaches. The most recent advances in acne therapy involve the use of combination treatments that address the numerous pathogenic factors that are at the root of the condition. The most recent literature on acne treatment, which described several topical applications, novel treatments, and emerging treatments for successful acne-targeted therapy, includes topical retinoid that normalize abnormal hyperkeratinization in the infundibulum and novel topical retinoid with anti-inflammatory properties. The present invention aimed to give a clear picture of new treatment medication strategy was produced. Also highlighted the dosage forms which are in various trial phases, along with successful and commercially available dosage forms in the market. The best results were found with nanoliposomal amphotericin B 0.4% topical gel. The study found a highly significant difference in mean recovery time between treatment groups (p < 0.001). The mean recovery time for the nanoliposomal amphotericin B 0.4% group was 2.87 ± 0.67 (1-4) weeks, which was the shortest time ever documented.
